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Abstract: Lung cancer is the leading cause of cancer-related death
in the United States. Outcomes for patients with lung cancer have
reached a plateau with cytotoxic chemotherapy. Lung cancer re-
mains very much at the vanguard of the new revolution in cancer
therapy using molecular targets. Although striking improvements in
survival have been observed in the treatment of chronic myeloid
leukemia, gastrointestinal stromal tumors, and in a subset of breast
cancer using this approach, the impact of targeted therapies in lung
cancer is quite modest. Along with advances in imaging and cancer
genomics, there is now considerable optimism that the pace of
progress in the treatment of lung cancer will accelerate in the next 10
years. As has been the custom for the past 8 years, leading experts
in the biology, diagnosis and treatment of lung cancer met for three
days to discuss current areas of research and future directions. This
summary provides a brief snapshot of the discussions held at the 8th
Annual Meeting on Targeted Therapies for Lung Cancer sponsored
by the International Association for the Study of Lung Cancer in
Santa Monica in early February 2008.
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The development of rationally designed, molecularly tar-geted therapy is one of the signature achievements of
cancer research in the last decade of the twentieth century.
Lung cancer remains very much at the vanguard of this new
revolution in cancer therapy. Along with advances in imaging
and cancer genomics, there is now considerable optimism
that the pace of progress in the treatment of lung cancer will
accelerate in the next 10 years. As has been the custom for the
past 7 years, leading experts in the biology, diagnosis and
treatment of lung cancer met for 3 days to discuss current
areas of research and future directions. This summary pro-
vides a brief snapshot of the discussions held at the 8th
Annual Meeting on Targeted Therapies for Lung Cancer
sponsored by the International Association for the Study of
Lung Cancer in Santa Monica in early February 2008. Al-
though the conference covered a broad range of topics and
issues, in the interest of space, this summary will be restricted
to a select few areas of research.
CELL CYCLE/CELL DIVISION-ASSOCIATED
PROTEIN INHIBITORS
Background
Cell cycle-associated proteins are currently considered
to be relevant anticancer targets for two reasons. First, ma-
lignant cells tend to have a higher mitotic index than most
normal adult tissues, so that interference with the cell cycle
will have a greater effect on the cancer cells than on most
normal tissues. While several proteins are involved in cell
cycle, this review will focus on four classes of inhibitors.
Aurora kinase inhibitors. The three mammalian aurora ki-
nases (A, B, and C) are centrosome -associated serine/threo-
nine kinases involved in spindle assembly, centrosome de-
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velopment, chromosome segregation, and cytokinesis during
mitosis and meiosis.
Kinesin spindle protein inhibitors. The kinesins are a large
family of eukaryotic ATP-driven, microtubule-associated
motor proteins. Two broad classes are recognized: those
involved in vesicle transport and those involved in mitosis.
Kinesin spindle protein is a mitotic kinesin, involved in
spindle pole separation and the maintenance of spindle
integrity.
CENP-E inhibitors. The mitotic checkpoint (or spindle
assembly checkpoint) acts to prevent chromosomal mis-
segregation and subsequent aneuploidy. Known mitotic
checkpoint genes include Mad1, Mad2, BubR1, and Bub3. The
centromere-linked, kinesin-like motor protein CENP-E also
contributes to the mitotic checkpoint, accumulating during
late G2, strengthening the interaction between chromosomes
and the spindle microtubules, and being degraded at the
completion of mitosis.
Polo-like kinase inhibitors. Four Polo-like kinases exist in
humans (Plk1–4). Plk1 is the best characterized member of
the family and is overexpressed in many different cancers.
Synopsis of Presentations
Aurora kinase inhibitors. Data were presented at this meet-
ing on Millenium’s 2 aurora A inhibitors, MLN8054 and
MLN8237. MLN8054 is a selective aurora A kinase inhibitor
(approximately 150-fold more potent against A than B). A
phase I dose escalation study of oral MLN8054 has com-
menced, utilizing both day1 to 7 and day1 to 14 dosing in a
21-day cycle, with sedation being reported as a dose-limiting
toxicity. Skin and tumor biopsies are being explored for
pHH3 accumulation and/or aberrant mitotic figures as phar-
macodynamic markers to potentially guide active dose selec-
tion. Phase I studies with MLN8237 are underway.
Kinesin spindle protein inhibitors. Phase I studies with the
GSK compound Ispinesib, and with Array’s ARRY-520 are
ongoing. To date kinesin spindle protein inhibitors seem to be
associated with neutropenia as the major dose-limiting tox-
icity. Monotherapy efficacy signals for Ispinesib have been
noted in the second or third-line treatment of advanced breast
cancer, with a reported 9% response rate in initial studies.
CENP-E inhibitors. Data were presented on GSK923295, a
potent and selective small molecule inhibitor of CENP-E. It
displays broad cytotoxic activity across many different pre-
clinical cancer models, including 24 out of 26 lung cancer
cell lines. A phase I dose escalation study of intravenously
administered GSK923295 is ongoing.
Polo-like kinase inhibitors. Data were presented on BI2536,
a potent and selective ATP-competitive inhibitor of Plk1.
Three phase I studies in advanced solid tumors or non-
Hodgkin lymphoma have been completed with 3 different
schedules where BI2536 was administered on day1, days 1 to
3, and days 1 and 8 intravenously on a q 21 day schedule.
Intermittent and dose-dependent neutropenia and thrombocy-
topenia have been the most prominent side effects reported to
date. Randomized phase II trials (two doses/schedules) in
second/third line non-small cell lung cancer (NSCLC); single
arm phase II studies in combination with pemetrexed in
second line NSCLC and as monotherapy in second line SCLC
have been initiated.
MET INHIBITORS
Background
Given the important role of aberrant HGF/MET signal-
ing in cancer, several different therapeutic strategies, aimed at
inhibiting HGF/MET signaling, have been developed and are
currently being evaluated in clinical trials. These include
agents that directly inhibit HGF and or its binding to MET,
antibodies targeted at MET and small molecule MET tyrosine
kinase inhibitors.
Synopsis of Presentations
MetMab. Dr. Merchant from Genentech presented data on
MetMAb. This is a monovalent antibody directed against the
MET receptor. The MetMAb is a humanized antibody and in
preclinical studies inhibited the HGF-induced proliferation of
Ba/F3 cells and HGF-induced migration of MDA-MB-435
cells. Preclinical studies demonstrated that MetMAb did not
lead to antibody-dependent cell-mediated cytotoxicity
(ADCC) in vitro. Furthermore, there have been no toxicities
observed so far in animal (monkey) studies. Based on these
findings and the in vitro and xenograft studies, MetMAb is
currently being evaluated in a phase I clinical trial.
INSULIN GROWTH FACTOR RECEPTOR
PATHWAY
Background
The insulin-like growth factor (IGF) signaling axis
plays an essential role in the balance between cellular prolif-
eration and apoptosis. Higher levels of IGF are seen in lung
tumor cells than normal tissue. IGF-1 receptor (IGFR-1R) as
well as its ligand IGF-2 is over expressed in NSCLC.
Synopsis of Presentations
CP751,871. CP751,871 is a fully humanized IgG2 subtype
monoclonal antibody with a half-life of 15 to 21 days that
targets the IGF-1 receptor. In phase I clinical trials
CP751,871 was well tolerated both as a monotherapy and
when given in combination with cytotoxic chemotherapy.
Single agent activity has been observed in Ewing sarcoma.
Results of a randomized phase II trial of chemotherapy plus
CP751,871 in NSCLC were reported by Dr. Karp at this
meeting.
In this phase II study in patients with stage III B/IV
NSCLC, patients were randomized to either the standard
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chemotherapy doublet of carboplatin (area under the curve 6)
and paclitaxel (200 mg/m2) alone or with 10 mg/kg to 20
mg/kg of CP751,871. A unique feature of this trial was that
patients in both arms were allowed to take maintenance
CP751,871 if they had not progressed after completing 6
cycles of either standard chemotherapy or chemotherapy plus
CP751,871. Additionally, those patients in the standard arm
who had progression of disease while on chemotherapy were
allowed to receive single agent CP751,871 at the discretion of
their treating physician.
This study highlighted potential toxicities of the use of the
use of IGF targeted therapy in NSCLC. The most common
grade 3 or 4 adverse events included dehydration (4% versus
0%) and hyperglycemia (20% versus 12%) which were
higher in the experimental arm compared with the chemo-
therapy alone arm. Grade 1 and 2 mucositis, cough, and
anemia were also reported in the CP751,871 arm. The overall
response rate 46% versus 32% favored the experimental arm.
When separated by histology, the response rates was greater
in patients with nonadenocarcinoma histology when treated
with IGF inhibitors and chemotherapy compared with che-
motherapy alone respectively (52% versus 33%). However,
patients with adenocarcinoma histology had response rates of
38% with and 30% without IGF inhibitor. Based on the
results of this randomized phase II study, 2 randomized
phase III trials in chemonaive patients with NSCLC are
being conducted one limited to non adenocarcinoma his-
tology and other open to all histologic types of NSCLC.
MK-0646. MK-0646 is a fully humanized monoclonal IgG1
antibody that selectively binds to the IGF-1 receptor and not
to the insulin receptor. Dr. Johnson presented an overview of
the compound and discussed a planned phase I/II study
combining MK-0646 with erlotinib. In preclinical modeling,
there is cross talk between the IGF and epidermal growth
factor receptor (EGFR) pathways which can lead to enhanced
tumor cell survival and proliferation. In lung cancer cells, the
up-regulation of IGF-1R has been implicated in both the
acquired and de novo resistance to EGFR targeting agents. In
vivo work demonstrates increased sensitivity to EGFR inhib-
itors when EGFR inhibitors are combined with compounds
that inhibit IGF-1R. Based on this observation, a phase I/II
clinical trial combining MK-0646 with erlotinib for patients
with refractory NSCLC is being conducted. In the phase II
portion, patients will be randomized to either single agent
erlotinib or the combination of erlotinib and MK-0646.
SRC AS A TARGET
Background
Dr. Faye Johnson reviewed the molecular structure,
tissue expression, and biology of Src family kinases (SFK) a
class of non receptor tyrosine kinases. There are nine known
members of SFK, which include Src, Blk, Fgr, Fyn, Hck,
Lck. Among SFK, Src is the most ubiquitously expressed
among epithelial cancers, including SCLC and NSCLC. It has
been suggested that Src activation occurs in approximately
50% of lung squamous cell carcinoma and 20% of adenocar-
cinoma. In vitro studies using Src inhibitor dasatinib led to
the abrogation of invasion in multiple lung cancer cell lines.
Furthermore, dasatinib also inhibits the growth of EGFR
mutant but not wild type cell lines. There are currently three
ATP-competitive inhibitors of SFK that are in clinical
trials: dasatinib, AZD0530 and SK1606/bosutinib. These
inhibitors demonstrate variable activity against multiple
SFK members including Src, as well as other tyrosine
kinases such as Abl, c-kit.
Synopsis of Presentations
Dr. Eric Haura reviewed the ongoing studies with
dasatinib. Although the relevant target of dasatinib in NSCLC
remains uncertain, dasatinib is currently in several phase II
trials, including in stage IIIB/IV chemonaive patients, pa-
tients who have progressed after erlotinib/gefinitib therapy
and in neoadjuvant setting for stage IB/II patients who will be
treated by surgery following 3 weeks of dasatinib to assess
the predictiveness of Src genomic signature for response.
Dr. David Gandara reported the preclinical studies of
AZD0503, which has higher IC50 (2.7 nM for Src and 4 nM
for Yes) and longer half-life (approximately 40 hours) than
dasatinib. AZD05030 blocks invasion and migration, as well
as inhibits growth or induce apoptosis in NSCLC cell lines.
Phase 1 trial of AZ0530 demonstrated a maximum tolerated
dose of 175 mg daily, which is in phase 2 clinical trials of
multiple cancer types, including NSCLC.
PROAPOPTOTIC AGENTS
Background
Apoptosis is mediated by 2 main molecular pathways to
promote activation of some members of the caspase family.
The intrinsic pathway is activated by signals stimulated by
cellular stress which lead to the release of cytochrome c from
mitochondria. This release is regulated by the B cell leuke-
mia/lymphoma (Bcl)-2 families of proteins, which consists of
both antiapoptotic and proapoptotic proteins. Cytotoxic can-
cer therapies predominantly induce apoptosis through stimu-
lation of the intrinsic pathway, and evasion can lead to
resistance to therapies. Signaling through the extrinsic path-
way is initiated by ligand binding and activation of proapop-
totic receptors, or death receptors (DR). These include Fas,
tumor necrosis factor (TNF) receptor and TNF-related apo-
ptosis inducing ligand (TRAIL) receptors. Once activated, the
receptor can form a death inducing signaling complex (DISC)
by recruiting the adapter protein, Fas-associated death do-
main (FADD) and caspases 8 and 10. This effectively induces
caspase activation, which lead to stimulation of effector
caspases to promote cell death.
Apomab: Anti-DR5 (TRAIL-R2) agonist. Apomab is a fully
human IgG1 monoclonal antibody, which acts as a highly
selective agonist to DR5 to induce the formation of a DISC,
recruit FADD, and initiate caspase activation.
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AMG 655: DR5 antibody. AMG 655 is another fully human
monoclonal antibody which is a specific agonist of DR5, and
stimulates the extrinsic apoptotic pathway through activation
of DR5.
Recombinant human Apo2L/TRAIL. Apoptosis ligand
2/TRAIL (Apo2L/TRAIL) is a proapoptotic protein that
binds to DR4 and DR5 (also known as TRAIL-R1 and
TRAIL-R2) to initiate programmed cell death through the
extrinsic pathway.
ABT-263: Small molecule inhibitor of Bcl-2. Bcl-2 is an
antiapoptotic protein within the intrinsic pathway, with oli-
gomerizes with other Bcl-2 proteins through the BH3 binding
domain. This oligomerization inhibits the activation of pro-
apoptotic proteins, such as Bax and Bak. ABT-263 is a
second-generation BH3 mimetic which blocks antiapoptotic
Bcl-2 family proteins at subnanomolar levels to stimulate
apoptosis. It is an oral, small molecule inhibitor of Bcl-2.
Synopsis of Presentations
Apomab: anti-DR5 (TRAIL-R2) agonist. Apomab has been
evaluated in the phase I setting in a multicenter, dose-
escalation trial. The most common grade 3 adverse event was
dyspnea, which occurred in 3 patients (8%). One dose-
limiting toxicity (DLT) occurred at the 10 mg/kg dose, a
grade 3 reversible transaminitis. Four patients achieved a
partial response including one each with bladder carcinoma,
renal cell carcinoma, sarcoma, and melanoma. Additional 17
patients maintained stable disease, including one patient with
lung cancer. Future studies with Apomab include phase II
investigations in advanced NSCLC as first-line therapy in
combination with carboplatin, paclitaxel and bevacizumab;
and second-line treatment for metastatic colorectal carcinoma
in combination with cetuximab and irinotecan.
AMG 655: DR5 antibody. A phase I investigation of AMG
655 in solid tumors has been reported. The drug was gener-
ally well tolerated; 3 grade 3 adverse events were reported
within the 0.3 mg/kg dose level (fatigue, n  1 and increased
lipase, n 2), and there were no grade 4 adverse events. One
patient experienced a PR, a patient with NSCLC in the 0.3
mg/kg cohort. Based on these results, AMG 655 is being
evaluated in a phase Ib/II trial for first-line therapy in stage
IIIB and IV NSCLC in combination with carboplatin and
paclitaxel at high and low doses of AMG 655. It will also be
investigated by the Southwest Oncology Group as front-line
therapy in combination with pemetrexed and cisplatin or
pemetrexed, cisplatin and bevacizumab, and as second-line
therapy in combination with pemetrexed.
Recombinant human Apo2L/TRAIL. A phase I trial evalu-
ated the safety and pharmacokinetics of recombinant human
Apo2L/TRAIL in solid tumors. Grade 3 adverse events in-
cluded, pneumonia (n  2), hyperglycemia and AST eleva-
tion. Drug-related DLTs were not reported in any patients,
but two patients with sarcoma experienced serious adverse
events related to tumor necrosis. One patient achieved a
partial response (at the 8 mg/kg dose level), and an additional
21 patients maintained stable disease. Further phase Ib and II
investigations are underway with Apo2L/TRAIL in advanced
NSCLC and will be studied as first-line therapy in combina-
tion with carboplatin, paclitaxel and bevacizumab.
ABT-263: Small molecule inhibitor of Bcl-2. A phase I/IIa
trial to evaluate the safety, pharmacokinetics, and preliminary
efficacy in patients with extensive stage small cell lung
cancer is ongoing. A planned 76 patients will be enrolled and
will receive 14 days of ABT-263 in escalating doses in a 21
day cycle. The molecule is not able to effectively inhibit
Mcl-1, which plays an important role in resistance to Bcl-2
inhibition and therefore, strategies to combine this therapy
with other targeted agents are in development.
HEAT SHOCK PROTEINS
Background
HSP 27. Heat shock protein (HSP) 27 is novel and attractive
target for therapy. HSP27 is a small 27 kD chaperone protein
that helps maintain the integrity of primarily cytoskeletal
proteins. It is strongly antiapoptotic. It can also work as a
cochaperone to HSP90. It is expressed in virtually all NSCLC
histologies, in over 75% of squamous cell carcinoma speci-
mens and well over 50% of adenocarcinoma specimens.
Staining is very specific. Expression in metastases generally
equals or exceeds that observed in primary specimens.
HSP 90. Hsp90 is a molecular chaperone required for the
stress-survival response, protein refolding, and the conforma-
tional maturation of a variety of signaling proteins. Its role in
tumor biology is similar to HSP27. Studies in vivo have
demonstrated that Hsp90 inhibitors have antitumor activity
when given alone or in combination with cytotoxic chemo-
therapy17-allylamino-17-demethoxygeldanamycin
(17-AAG) is a prototypical ansamycin antibiotic inhibitor of
Hsp90 and results in the degradation of client proteins via the
ubiquitin-proteasome pathway.
Synoposis of Presentations
HSP 27. A potential candidate agent, antisense OGX-427
has led to 70 to 90% suppression in 2 separate cell lines
(A549 and H358). To review, antisense oligonucleotides
(ASOs) are single strands of short desoxynucleotide se-
quences (18–21 oligomers) that bind in a sequence-specific
manner (based on Watson-crick base pair interactions) to the
targeted mRNA of a particular gene, thus preventing gene
transcription. The benefits of HSP27-ASOs do not appear to
be concentration-dependent. Viability assays show that
HSP27-ASO not only lead to a decrease in cell growth, but
actually kill cells in both models. Phase I studies of these
agents are ongoing.
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HSP 90. The early trials of 17-AAG have been marked by
significant toxicities. Toxicities include hepatitis, fatigue,
myalgias, and nausea, with the latter likely attributable, in
part, to the DMSO-based formulation. Induction of a heat
shock response and down-regulation of Akt and Raf-1 were
observed in biomarker studies. It seems that the toxicity
profile of 17-AAG is schedule dependent. Intermittent dosing
schedules, which proved less toxic, were recommended for
future phase II studies.
Based on the in vitro synergy between 17-AAG and
paclitaxel, a phase I study has defined a recommended
phase II dose for this combination with twice-weekly
17-AAG at a dose of 175 mg/m2 in combination with
weekly paclitaxel 80 mg/m2.
HISTONE DEACETYLASE (HDAC) INHIBITORS
Background
Histone deacetylase (HDAC) inhibitors are novel anti-
cancer agents that act by a variety of mechanisms. Histones
are the core proteins in the center of the DNA double helix.
The DNA double helix exists in either a nonacetylated,
transcriptionally inactive configuration or an acetylated state
that is open to gene transcription. The dynamic equilibrium
between the acetylated and nonaceylated forms is mediated
by histone acetyltransferase and histone deacetylase. The
HDAC family consists of class I proteins (HDAC 1, 2, 3, 8,
and 11), class IIa (HDAC 4, 5, 7, and 9), class IIB (HDAC 6,
and 10), and sirtuins. Inhibition of HDAC results in expres-
sion of a number of important genes such as key tumor
suppressor genes that are silenced in cancer cells. This has
provided the rationale to evaluate various HDAC inhibitors
for the treatment of cancer. The anticancer effects of HDAC
inhibitors are also attributed to their effects on nonhistone
targets. HDAC inhibitors that are currently under develop-
ment are categorized by their chemical structure into short
chain fatty acids (butyrate, phenyl butyrate, valproic acid),
hydroxamic acid derivatives (vorinostat, panabinostat, tricho-
statin A, LAQ824), cyclic tetrapeptides (trapoxins, FK 228,
apicidin), and benzamides (SDX275, CCI 994). Many of
these agents have entered the clinic and are under investiga-
tions for the treatment of various hematologic and solid organ
malignancies, including lung cancer.
Synopsis of Presentations
Dr. Belani provided an update on the ongoing studies
with vorinostat, a novel HDAC inhibitor. Vorinostat binds to
the catalytic site of HDAC and blocks substrate access to the
active zinc ion. It targets select members of the class I and II
HDACs. Out of the 19 patients with advanced NSCLC
treated with paclitaxel, carboplatin and vorinostat, there were
10 partial responses and four patients had disease stabiliza-
tion. The promising activity noted in this phase I study has
prompted a randomized phase II study for patients with
previously untreated advanced NSCLC.
Dr. Bunn provided an update on SDX 275, an orally
administered inhibitor of HDAC. This agent is administered
either once a week or twice weekly and has been given to
over 250 patients in various studies. It is tolerated well with
nausea, hypophosphatemia, and fatigue being the common
side effects. In NSCLC, SDX 275 is being developed in
combination with erlotinib in 2 phase II studies.
Dr. Witta and colleagues are conducting a phase II
study that randomizes patients with advanced NSCLC pro-
gressing after one or two previous chemotherapy, to erlotinib
and placebo or erlotinib in combination with SDX 275. The
primary end point of this study is the determination of
progression-free survival.
Dr. Blumenschein provided a summary on the devel-
opment of LBH589, a pan HDAC inhibitor. This agent has
completed phase I evaluation. It is tolerated well upon oral
administration. In the phase I studies, disease stabilization
was noted in patients with malignant pleural mesothelioma,
renal cell carcinoma, and melanoma. The common adverse
events include nausea, diarrhea, fatigue, and thrombocytope-
nia. Combination studies with chemotherapy and bevaci-
zumab are underway.
VACCINE THERAPY
Background
The novel immune strategies attempt to modulate the
host- tumor direct immune response, produce a novel antitu-
mor immune reaction, or in the case of adoptive therapy
provide the patient with active antitumor effecter cells. This
report provides some background on the biology of Toll-like
receptor 9 (TLR9), an update on immune strategies modulat-
ing host-tumor receptor immune response (anti-CTLA-4anti-
bodies), and on the production of novel antitumor immune
reactions (TGF-B2 vaccine; L-BLP25 vaccine and the
MAGE-A3 vaccine).
Synopsis of Presentations
Toll-like receptor 9. The human immune system recognizes
pathogens (viral, bacterial, etc) using a family of receptors.
The best understood ones are a family of 10 related molecules
called the Toll-like receptors. The immune role of toll-like
receptor 9 (TLR-9) has been the most extensively studied.
The activation of TLR9 results in a cascade of innate and
adoptive immune responses including the secretion of cyto-
kines, the activation of NK cells and expansion of Th1
lymphocytes. As a result a potent cell mediated Th1 response
is initiated. Several synthetic oligodeoxynuleotide agonists
(ODN) for TLR9 are currently in development. CPG 7909
(Coley Pharmaceuticals Group) is being investigated as a
vaccine against several tumor groups including NSCLC. The
ODN CPG 7909 has been combined with an anti-MAGE 3
recombinant protein vaccine and in a phase I/II study durable
responses have been seen.
Anti-CTLA-4 antibodies. One promising approach of mod-
ulating host immune response can be achieved by augmenting
endogenous T cell mediated immunity by interrupting the T
cell down regulatory pathways that contribute to immune
tolerance thereby boosting signaling and enhancing activa-
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tion. Two anti-CTLA-4 monoclonal antibodies are discussed
here, the first agent Tremelimumab, an IgG2 antibody (Pfizer,
New York CP 675,206) and the second Ipilimumab an IgG1
antibody (Bristol-Myers Squibb, New York, BMS 734016,
MDX-010). Both agents binding to CTLA-4 with a high
affinity in the submicromolar range. Clinically, there is pre-
liminary evidence of tumor regression and prolonged time to
progression in a variety of tumors including melanoma,
ovarian, prostate and renal cell carcinoma with these agents.
A randomized phase II trial exploring maintenance Tremeli-
mumab in Stage III B (with pleural effusion) or IV NSCLC
following platinum based chemotherapy has completed ac-
crual. A randomized double blind, multicenter phase II study
evaluating the efficacy and safety of Ipilimumab (BMS-
734016) in combination with paclitaxel and carboplatin com-
pared with palcitaxel and carboplatin alone in previously
untreated lung cancer is ongoing. Patients with stage IIIb/IV
NSCLC and those with extensive disease SCLC are being
enrolled.
TGF-B2 vaccine. Transforming growth factor beta (TGF-B)
is one of a family of multifunctional proteins that regulate
growth and function of normal and neoplastic cells. In par-
ticular, elevated levels of TGF-B2 are linked to immunosu-
pression in cancer patients and the level of TGF-B2 is
inversely correlated with prognosis in patients with NSCLC.
The results of a recently completed phase II study of a
TGF-B2 antisense gene based vaccine belagenpumatucel-L
(Lucanix, Novarx Corporation) are discussed here. The only
toxicity seen in early phase II study was grade 1 erythema at
the vaccine site of injection. The median survival of 61
patients enrolled with stage IIIB/IV was 14.4 months with a
56% one year and 33% 2-year survival. There appeared to be
a dose response with a median of 6.9, 14.9 and 15.9 months
at 1.25, 2.5, and 5.0 107 cells/injection, respectively. Based
on these encouraging results a randomized phase III study of
vaccine at 2.5  107 cells/injection delivered monthly in
patients with stage IIIB/IV NSCLC who have attained at best
stable disease following standard chemotherapy has com-
menced accrual. Patients are randomized to the vaccine or
best supportive care.
L-BPL25 vaccine. L-BLP25 (STIMUVAX) is a liposomal
bipeptide attached to a monophosphoryl lipid A adjuvant.
This vaccine has been studied in a randomized, open-label,
controlled, multi center phase IIB study in untreated stage
IIIB and IV NSCLC who achieved stable disease following
platinum based chemotherapy. One hundred seventy-one pa-
tients were randomized and the median overall survival was
17.2 months with vaccine therapy compared with only 13.0
months with best supportive care only (HR 0.75; 95% CI:
0.533–1.042) Patients with stage III B only (n  65) had
significantly better outcomes with vaccine therapy compared
with best supportive care only; median survival was 30.6
versus 13.3 months; 1-year survival 69% versus 57%; 3-year
survival 49% versus 27% (HR 0.55;95% CI: 0.301–0.999),
respectively. These results have led to a large randomized,
placebo controlled phase III study (START) in unresectable
stage IIIA and IIIB NSCLC patients who have responded or
have stable disease following prior chemoradiation. The iden-
tical regimen used in the phase II study will be assessed in
1322 patients randomized 2:1 to vaccine or placebo.
MAGE-A3 vaccine
The MAGE-A3 tumor antigen is not expressed on
normal cells. It is a tumor specific antigen identified and
expressed in 35 to 50% of lung cancer. Combining the
purified recombinant protein (Ag) with an adjuvant has pro-
duced the MAGE-A3 vaccine. A recent randomized phase II
study has had encouraging results. In this study, patients with
pathologic stage IB (T2N0) and II (T1–2; N1;T3 NO) whose
tumors were MAGE-A3 positive and who had undergone a
complete resection There was a trend in favor of the vaccine
arm for both progression free survival (HR 0.73; 95% CI:
0.45–1.16) and overall survival (HR 0.66;95% CI: 0.36–
1.20). As a consequence, a large randomized, double blind,
placebo controlled, phase III study (MAGRIT–MAGE A3 as
Adjuvant Non Small Cell Lung Cancer Immunotherapy) in
completely resected pathologic stage IB, II and IIIA has been
initiated.
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